Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
Diagnostic Laboratory Immunology

Role of Serum Mycoplasma pneumoniae IgA, IgM, and IgG in the Diagnosis of Mycoplasma pneumoniae-Related Pneumonia in School-Age Children and Adolescents

Wei-Ju Lee, Eng-Yen Huang, Chih-Min Tsai, Kuang-Che Kuo, Yi-Chuan Huang, Kai-Sheng Hsieh, Chen-Kuang Niu, Hong-Ren Yu
Helene F. Rosenberg, Editor
Wei-Ju Lee
aDepartment of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Graduate Institute of Clinical Medical Science, Chang Gung University College of Medicine, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eng-Yen Huang
bDepartment of Radiation Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Graduate Institute of Clinical Medical Science, Chang Gung University College of Medicine, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chih-Min Tsai
aDepartment of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Graduate Institute of Clinical Medical Science, Chang Gung University College of Medicine, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuang-Che Kuo
aDepartment of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Graduate Institute of Clinical Medical Science, Chang Gung University College of Medicine, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Chuan Huang
aDepartment of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Graduate Institute of Clinical Medical Science, Chang Gung University College of Medicine, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai-Sheng Hsieh
aDepartment of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Graduate Institute of Clinical Medical Science, Chang Gung University College of Medicine, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chen-Kuang Niu
aDepartment of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Graduate Institute of Clinical Medical Science, Chang Gung University College of Medicine, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong-Ren Yu
aDepartment of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Graduate Institute of Clinical Medical Science, Chang Gung University College of Medicine, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helene F. Rosenberg
IIS/LAD/NIAID/NIH
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CVI.00471-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Mycoplasma pneumoniae is an important causative pathogen of community-acquired pneumonia in children. Rapid and reliable laboratory diagnosis of M. pneumoniae infection is important so that appropriate antibiotic treatment can be initiated to reduce the misuse of drugs and resistance rates. Anti-M. pneumoniae immunoglobulin M (IgM) is an indicator of recent primary infection but can persist for several months after initial infection. It has been suggested that anti-M. pneumoniae immunoglobulin A (IgA) can be a reliable indicator for recent M. pneumoniae infection in adults. We investigated the clinical diagnostic value of M. pneumoniae IgA in school-age children and adolescents with M. pneumoniae-related pneumonia. Eighty children with pneumonia and seropositive for M. pneumoniae IgM or with a 4-fold increase of anti-M. pneumoniae immunoglobulin G (IgG) were enrolled from May 2015 to March 2016. The titers of M. pneumoniae IgA, IgM, and IgG, the clinical features, and laboratory examinations of blood, C-reactive protein, and liver enzymes were analyzed. The initial positivity rates for M. pneumoniae IgM and IgA upon admission to the hospital were 63.6 and 33.8%, respectively. One week after admission, the cumulative positivity rates for M. pneumoniae IgM and IgA increased to 97.5 and 56.3%, respectively. Detection of M. pneumoniae IgM was more sensitive than detection of M. pneumoniae IgA for the diagnosis of M. pneumoniae-related pneumonia in school-age children and adolescents; however, paired sera are necessary for a more accurate diagnosis.

INTRODUCTION

Mycoplasma pneumoniae is one of the most common atypical pathogens causing pneumonia, especially in school-age children and adolescents. Cases occur in all seasons but predominantly in the spring and autumn. Although a significant cough without rhinorrhea is the typical manifestation, the symptoms can vary from an asymptomatic respiratory infection to severe pneumonia (1). M. pneumoniae is generally susceptible to macrolide or tetracycline antibiotics, but these treatments are not often immediately used for cases of community-acquired pneumonia if no optimal detecting tool for M. pneumoniae exists. Although M. pneumoniae is also susceptible to fluoroquinolone, its utilization in children is limited due to its side effect of joint toxicity (2). In recent years, macrolide-resistant M. pneumoniae has become more and more prevalent across the world, partly due to the wide use of macrolides (3). The macrolide resistance rate of M. pneumoniae is about 10 to 20% in Taiwan (4, 5), and upward of 90 to 100% in China, the neighboring country of Taiwan (3). Therefore, an optimal detection method is needed to allow for a more precise diagnosis, and thus the appropriate treatment of patients with M. pneumoniae-related pneumonia, and reduce the misuse of antibiotics.

M. pneumoniae is difficult to culture and has a very low growth rate, and thus culture-based approaches are usually not helpful clinically. The clinical use of PCR assays for the diagnosis of M. pneumoniae respiratory infections has been reported in both adults (6–9) and children (10–14). However, inducing sputum samples is difficult in young children, and some reports have shown no obvious differences between M. pneumoniae PCR positivity rates of throat swabs from individuals with suspected cases of M. pneumoniae infection and those of healthy subjects (15). This suggests that M. pneumoniae may colonize the upper airway in humans without inducing disease. Since the pathogen-induced immune response results in the production of antibodies, serological testing is a major diagnostic tool for the detection of M. pneumoniae infection. The complement fixation test has also been used; however, the complex nature of the technique and its high false-positivity rate limit its use (16, 17). The detection of M. pneumoniae IgM has been used to determine the presence of an acute infection. However, some patients do not have sufficient levels of M. pneumoniae IgM antibodies to allow for detection during the early stages of acute infection or reinfection (18), and some patients may have detectable levels of M. pneumoniae IgM for several months after M. pneumoniae infection (19). Both of these situations can lead to difficulties in making a clinical diagnosis. Only a few studies have reported on the use of M. pneumoniae IgA antibodies for the diagnosis of M. pneumoniae infection in the past 2 decades. One study reported that detection of M. pneumoniae IgA is more sensitive than that of IgM in diagnosing acute M. pneumoniae-related pneumonia in adults (20), whereas another reported lower sensitivity in detecting M. pneumoniae IgA in young children (21). However, M. pneumoniae-related pneumonia often occurs in school-age children and adolescents. To date, no study has focused on the diagnostic value of M. pneumoniae IgA in school-age children. Therefore, the aim of this study was to investigate the clinical significance and usefulness of detecting M. pneumoniae IgA in school-age children and adolescents with community-acquired pneumonia caused by M. pneumoniae.

RESULTS

Clinical characteristics of enrolled patients.A total of 89 children with M. pneumoniae IgM-positive serum were enrolled in this study, of whom nine (10.1%) were excluded due to persistently low positive M. pneumoniae IgM titers without a 2- or 4-fold increase in M. pneumoniae IgG titers after 2 weeks of follow-up. The remaining 80 children (seroconversion, n = 26; IgM 2-fold increase: n = 72; IgG 4-fold increase: n = 31 [Fig. 1]) (31 males, 49 females; mean age, 6.6 ± 3.3 years old [range, 3 to 17 years old]) were entered into the analysis, and 215 serum samples were obtained. The duration of fever (≥38°C) before admission was 4.3 ± 2.7 days, as reported by the patient or a family member. The clinical characteristics, including age, duration of fever, hospital stay, and laboratory analysis of blood, liver enzymes, and C-reactive protein (CRP) are presented in Table 1.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Venn diagram showing serologically diagnostic criteria for the 80 children with M. pneumoniae-related pneumonia. The intersection areas among these three circles show cases that simultaneously fit the different diagnostic criteria.

View this table:
  • View inline
  • View popup
TABLE 1

Clinical characteristics and laboratory results for blood, liver function, and C-reactive protein for 80 patients with M. pneumoniae infectiona

Detection of M. pneumoniae IgM was more sensitive than M. pneumoniae IgA in school-age children with M. pneumoniae-related pneumonia.Among the 80 cases, the positivity rates for M. pneumoniae IgA, IgM, and IgG upon admission were 33.8% (27/80), 63.8% (51/80), and 32.5% (26/80), respectively (Fig. 2). Of note, 21 cases (26.2%) were initially serum negative for M. pneumoniae IgA, IgM, and IgG. A chi-square test showed significant differences between the initial positivity rates of M. pneumoniae IgA and IgM (P = 0.019). Then, we analyzed the correlation between initial M. pneumoniae IgA, IgM, and IgG values and the duration of fever before hospitalization, and the results showed that M. pneumoniae IgM titers, but not IgA or IgG titers, were significantly positively correlated with the duration of fever before hospitalization (r = 0.377, P = 0.002) (Fig. 3). In order to determine the relevance between the M. pneumoniae antibody titer and fever duration before admission, we divided the patients into three groups according to the duration of fever before hospitalization to compare the positivity rates of M. pneumoniae IgA and IgM as follows: (i) 0 to 3 days, (ii) 4 to 6 days, and (iii) 7 to 14 days. Most of the patients (40% [32/80]) had a fever duration of fewer than 3 days before hospitalization. Twenty-seven patients (33.8%) and 21 patients (26.3%) had a fever duration of 4 to 6 days and 7 to 14 days before hospitalization, respectively. As shown in Fig. 4, both M. pneumoniae IgA and IgM positivity rates were higher in patients with a longer fever duration before hospitalization. In addition, the serum positivity rate of M. pneumoniae IgM was higher than that for M. pneumoniae IgA in all groups (Fig. 4), suggesting that the detection of M. pneumoniae IgM is more sensitive than M. pneumoniae IgA detection at any stage of disease for school-age children with M. pneumoniae-related pneumonia.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Venn diagram showing the case numbers initially positive for Mycoplasma pneumoniae IgA (27, 33.8%), IgM (51, 63.8%), and IgG (26, 32.5%) upon hospital admission. Twenty-one cases were negative for M. pneumoniae IgA, IgM, and IgG upon admission.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

Correlation of initial M. pneumoniae IgA, IgM, and IgG values with duration of fever upon admission. M. pneumoniae IgM but not IgA or IgG values were significantly positively correlated with the duration of fever (Pearson's correlation coefficient: IgA, r = 0.240, P = 0.052; IgM, r = 0.377, P = 0.002; and IgG, r = −0.016, P = 0.902).

FIG 4
  • Open in new tab
  • Download powerpoint
FIG 4

Positivity rates for M. pneumoniae IgA, IgM, and IgG with different durations of fever upon admission. The patients were divided into three groups based on the duration of fever upon admission (0 to 3 days, 4 to 6 days, and 7 to 14 days); all of them had a higher positivity rate for M. pneumoniae IgM than for M. pneumoniae IgA.

Paired serum follow-up is needed for patients who are initially M. pneumoniae IgM negative but clinically symptomatic.We next compared the cumulative positivity rates for M. pneumoniae IgA, IgM, and IgG within 1 month of hospitalization. Since the patients were at different time points in the disease course on admission to the hospital, blood samples were taken according to their clinical condition but not on the same schedule. In order to organize the serological data of the patients, blood sample data were divided into five groups according to the hospitalization stay after admission: (i) baseline (the day of admission), (ii) 2 to 4 days, (iii) 5 to 7 days, (iv) 8 to 14 days, and (v) 15 to 28 days. The initial M. pneumoniae IgM positivity rate for all 80 patients was 63.8% (51/80) (Fig. 5A). The cumulative positivity rates for M. pneumoniae IgM for groups 2 and 3 after admission were 85.0 and 97.5%, respectively. Twenty-six of the 80 cases (32.5%) showed seroconversion of M. pneumoniae IgM 1 week after admission. These findings suggested that paired serum follow-up samples are needed for patients who are initially M. pneumoniae IgM negative but are clinically symptomatic. The cumulative positivity rate of M. pneumoniae IgM was always higher than that of M. pneumoniae IgA, even though 25 of the 80 patients were still serum negative for M. pneumoniae IgA 15 to 28 days after admission.

FIG 5
  • Open in new tab
  • Download powerpoint
FIG 5

Cumulative positivity rate of M. pneumoniae IgA, IgM, and IgG. (A) The cumulative positivity rate for M. pneumoniae IgA, IgM, and IgG among all 80 patients was calculated for five time intervals after admission: 0, 2 to 4, 5 to 7, 8 to 14, and 15 to 28 days. (B) Cumulative positivity rates for M. pneumoniae IgA, IgM, and IgG for 26 cases with seroconversion. Twenty-six cases were initially negative for M. pneumoniae IgM and then experienced seroconversion after 2 weeks. Only four cases (15.4%) were initially positive for M. pneumoniae IgA. The cumulative positivity rate for M. pneumoniae IgM was higher than for IgA after 2 days (61.5% versus 46.2%, respectively).

Among the 80 patients with pneumonia due to M. pneumoniae, 26 (32.5%) who were initially negative for M. pneumoniae IgM upon admission showed seroconversion after 2 weeks of follow-up (Fig. 5B). These findings showed the natural course of M. pneumoniae antibodies in these patients. Among the 26 patients who were initially negative for M. pneumoniae IgM, four (15.4%) were initially positive for M. pneumoniae IgA; however, the cumulative positivity rate for M. pneumoniae IgM was also higher than that for M. pneumoniae IgA after 2 to 4 days of follow-up (61.5% versus 46.2%) in all enrolled cases (Fig. 5B). These findings also suggest the clinical importance of paired serum follow-up.

We also analyzed the levels of M. pneumoniae IgA, IgM, and IgG after 1 month of follow-up, and all of the patients were still positive for all antibodies after 15 to 28 days of follow-up (Fig. 6).

FIG 6
  • Open in new tab
  • Download powerpoint
FIG 6

Titers of M. pneumoniae IgA, IgM, and IgG after follow-up for 1 month. The means and standard errors of the M. pneumoniae IgA, IgM, and IgG titers were classified into five time intervals: 0, 2 to 4, 5 to 7, 8 to 14, and 15 to 28 days after admission. None of the titers showed any significant decline after 1 month of follow-up.

Fever duration before admission and the initial platelet count were positively correlated with the initial M. pneumoniae IgM value.In order to establish what factors can influence the M. pneumoniae IgM titer, we analyzed the correlation between the patients' initial M. pneumoniae IgM value, their clinical features, and the results of the laboratory analysis of blood, liver function, and CRP using Pearson's correlation analysis. We found that fever duration before admission and initial platelet count were positively correlated with initial M. pneumoniae IgM titers (Table 1 and Fig. 7A and B). The associations between the clinical characteristics, laboratory analysis of blood cells, liver enzymes and CRP, and M. pneumoniae IgM titer were then tested again using multivariate logistic regression. This result also indicated that fever duration before admission and the platelet count were positively correlated with M. pneumoniae IgM (P = 0.005 and P = 0.001, respectively). However, the correlation between the fever duration before admission and platelet count was not significant (r = 0.075, P = 0.638) (Fig. 7C). This suggests that both fever duration before admission and the initial platelet count are independent factors correlated with M. pneumoniae IgM titer.

FIG 7
  • Open in new tab
  • Download powerpoint
FIG 7

Correlation between the duration of fever before admission, the platelet count, and the level of M. pneumoniae IgM. (A) There was no significant correlation between fever duration before admission and platelet count (P = 0.638). (B) There was significant correlation between M. pneumoniae IgM and platelet count (P = 0.004). (C) There was significant correlation between M. pneumoniae IgM and fever duration before admission (P = 0.014).

DISCUSSION

In this study, we investigated longitudinal changes in M. pneumoniae IgA, IgM, and IgG titers in school-age children with pneumonia caused by M. pneumoniae infection. We found that the initial positivity rates for M. pneumoniae IgM and IgA upon admission to hospital were 63.8 and 33.8%, respectively. The duration of fever before admission and platelet count were positively correlated with initial M. pneumoniae IgM titers, and the cumulative positivity rates for M. pneumoniae IgM and IgA increased to 97.5 and 56.3%, respectively, 1 week after admission. Detection of M. pneumoniae IgM was more sensitive than detection of M. pneumoniae IgA in the diagnosis of school-age children and adolescents with pneumonia caused by M. pneumoniae.

The progression of Mycoplasma infection is often gradual and slow and, in adults, the illness is usually present for more than 1 week before the patient seeks medical assistance (20). However, our results showed that children with pneumonia caused by M. pneumoniae were mostly admitted to hospital within the first week of infection (mean, 4.3 ± 2.7 days). This may be because fever is the major symptom in children rather than the prolonged cough typically seen in adults infected with M. pneumoniae. Children are therefore brought to the hospital sooner than adults due to the concerns of the caregiver. For this reason, we found that many cases (21/80 [26.3%]) were negative for M. pneumoniae-specific antibodies upon admission. In order to avoid missing false-negative cases, we collected paired sera for M. pneumoniae IgA, IgM, and IgG after admission. However, since fever duration before admission was reported by the patients or family members, there is a limitation for the accuracy of this value. Beersma et al. reported high background rates of seropositivity for M. pneumoniae IgM in some adult populations, ranging from 0 to 51% depending on the assay used (22). In the present study, nine children were excluded due to persistently low positive M. pneumoniae IgM titers with no obvious increase in the paired sera. The background seropositivity rate for M. pneumoniae IgM was 10.1% in the children in this study.

In previous studies, the detection of M. pneumoniae IgA has been reported to be a good indicator of recent M. pneumoniae infection in predominantly adult populations (23–25). Detection of M. pneumoniae IgA has been reported to be more sensitive than detection of M. pneumoniae IgM for the diagnosis of M. pneumoniae infection in adults (20). However, conflicting results have been reported in toddlers, for whom M. pneumoniae IgA was reported to be a poor indicator of M. pneumoniae infection (21). In this study, we investigated the diagnostic value of M. pneumoniae IgA in diagnosing pneumonia caused by M. pneumoniae in school-age children, the most common age for infection with this pathogen. Our results showed positivity rates for M. pneumoniae IgM and IgA on the first day of hospital admission of 63.8 and 33.8%, respectively, and these rates were positively correlated with the duration of fever before admission (Fig. 2). We also found that the positivity rate for M. pneumoniae IgM was higher than that of M. pneumoniae IgA for each duration of fever before admission group (Fig. 3). This suggests that detection of M. pneumoniae IgA is less sensitive than detection of M. pneumoniae IgM for the diagnosis of M. pneumoniae-related pneumonia in school-age children and adolescents. The reason that M. pneumoniae IgA is a good marker in adults but not in children with M. pneumoniae-related pneumonia is unclear. The developing immune system may partly explain this phenomenon. Human serum IgA and IgM concentrations change with age, with lower concentrations at birth. Serum IgM reaches an adult concentration at 4 to 5 years of age, whereas serum levels of IgA mature slowly until puberty (26, 27). Additional studies are needed to investigate this issue further.

In the present study, the positivity rate for M. pneumoniae IgM upon hospital admission was 63.8%, with a mean duration of illness of 4.3 ± 2.7 days prior to admission. This is consistent with another study in which the M. pneumoniae IgM positivity rate in children was 62.2% in the first week (28) and ca. 70.9 to 81.8% in the second week (29, 30) of the illness. The sensitivity of serological tests can be affected by the timing of specimen collection, the standard of diagnosis, and the assay used (31). This could explain the higher sensitivity of M. pneumoniae IgM in patients with a longer duration of illness prior to admission (Fig. 2B and Fig. 3). We found a positive correlation between the M. pneumoniae IgA positivity rate and the duration of illness prior to admission, although this correlation was less significant than that for M. pneumoniae IgM (Fig. 2A).

A 4-fold increase in M. pneumoniae IgG titers in acute- and convalescent-phase sera is considered to be the gold standard for the diagnosis of acute M. pneumoniae respiratory infection (32). The rate of 4-fold increase in M. pneumoniae IgG in paired sera varies in different studies. Medjo et al. reported that 90% of cases had a 4-fold increase in M. pneumoniae IgG in patients with positive throat swabs via PCR (29). In comparison, Ma et al. reported that only 2.4% of cases had a 4-fold increase in M. pneumoniae IgG in patients with positive IgM or positive nasopharyngeal swabs via PCR (30). In the present study, 31 cases (38.8%) had a 4-fold increase in M. pneumoniae IgG in paired sera. Since M. pneumoniae IgG in paired sera cannot provide an instant diagnosis and as obtaining second blood samples from children can be difficult in the convalescence phase, M. pneumoniae IgG does not seem to be an optimal tool for the early diagnosis of M. pneumoniae infection.

In addition to the duration of fever before admission, we found a positive correlation between M. pneumoniae IgM titers and platelet count upon hospital admission. This may be explained by the production of immunoglobulin after an illness. However, this correlation has not previously been reported in the literature. It has been reported that chronic inflammation is often associated with reactive thrombocytosis (33). Youn et al. reported a correlation between platelet count and serum status of M. pneumoniae IgM, where the platelet count was higher in a subgroup with increased M. pneumoniae IgM than in those with seroconversion (34). In the present study, the platelet count was also higher in the subgroup with increased M. pneumoniae IgM levels than in that of the seroconverted cases (292,090 ± 73,530/μl versus 227,850 ± 63,730/μl, respectively; P < 0.001). Furthermore, we found that the platelet count was significantly positively correlated with the M. pneumoniae IgM titer, which could explain the lower platelet count in the seroconverted cases.

In conclusion, detection of M. pneumoniae IgM was more sensitive than detection of M. pneumoniae IgA for the diagnosis of M. pneumoniae-related pneumonia in school-age children and adolescents. If only one serum sample for M. pneumoniae IgM was tested at initial admission, there was a 10.1% false-positivity rate and a 32.5% false-negativity rate. For a more accurate diagnosis of M. pneumoniae-related pneumonia in school-age children, testing of paired sera of M. pneumoniae IgM is still necessary.

MATERIALS AND METHODS

Patients.We enrolled patients aged 3 to 18 years who were admitted to Kaohsiung Chang Gung Memorial Hospital between May 2015 and March 2016. All of the patients had a cough, fever, and chest X-ray-confirmed bronchopneumonia or lobar pneumonia, suggesting a lower respiratory tract infection. Fever was defined as a body temperature of ≥38.0°C, as measured by infrared tympanic membrane thermometers. All patients were diagnosed serologically, and exhibited seroconversion or an increase in antibody titers (2-fold increase of serum M. pneumoniae IgM or a 4-fold increase in M. pneumoniae IgG) for at least 2 weeks after admission (35). The patients enrolled in this study were otherwise healthy without any underlying conditions that might have altered their clinical course of disease.

Methods.All patients received macrolide antibiotic treatment, after which all of the patients improved clinically. The serum levels of M. pneumoniae IgA, IgM, and IgG were determined upon admission and at various time points during or after admission depending on their clinical condition. Serum M. pneumoniae IgM and IgG were assayed using ELISA ImmunoWELL kits (Ben-Bio, San Diego, CA), and serum M. pneumoniae IgA was assayed using CHORUS kits (Diesse Diagnostica Senese, Siena, Italy) according to the manufacturers' instructions. The positive cutoff values for M. pneumoniae IgA, IgM, and IgG were 18 arbitrary units (AU)/ml (with upper and lower limits of 10 and 100 AU/ml), 950 AU/ml, and 320 AU/ml, respectively. The Institutional Review Board of Kaohsiung Chang Gung Memorial Hospital approved the entire study (103-7061A3). The values and positivity rates for M. pneumoniae IgA, IgM, and IgG were correlated with the clinical features. Continuous variables are expressed as means ± standard errors. The chi-square test was used to determine differences in initial positivity rates of M. pneumoniae IgA and IgM. Statistical correlations between M. pneumoniae IgM titers, clinical characteristics, and the results of laboratory analysis of blood, liver function, and C-reactive protein (CRP) were determined using Pearson's correlation test and multivariate logistic regression. All statistical tests were performed using SPSS version 19.0 for Windows (SPSS, Inc., Chicago, IL). A P value of <0.05 indicated statistical significance.

ACKNOWLEDGMENTS

This study was supported in part by grants CMRPG8E0011 (W.-J.L.) and MOST 105-2314-B-182-051-MY2 (H.-R.Y.) from the Ministry of Science and Technology, Taiwan. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

FOOTNOTES

    • Received 1 October 2016.
    • Returned for modification 4 October 2016.
    • Accepted 7 October 2016.
    • Accepted manuscript posted online 19 October 2016.
  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Ali NJ,
    2. Sillis M,
    3. Andrews BE,
    4. Jenkins PF,
    5. Harrison BD
    . 1986. The clinical spectrum and diagnosis of Mycoplasma pneumoniae infection. Q J Med58:241–251.
    OpenUrlPubMed
  2. 2.↵
    1. Bradley JS,
    2. Jackson MA
    ,Committee on Infectious Diseases, American Academy of Pediatrics. 2011. The use of systemic and topical fluoroquinolones. Pediatrics128:e1034–1045. doi:10.1542/peds.2011-1496.
    OpenUrlCrossRef
  3. 3.↵
    1. Pereyre S,
    2. Goret J,
    3. Bebear C
    . 2016. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol7:974.
    OpenUrlCrossRef
  4. 4.↵
    1. Wu PS,
    2. Chang LY,
    3. Lin HC,
    4. Chi H,
    5. Hsieh YC,
    6. Huang YC,
    7. Liu CC,
    8. Huang YC,
    9. Huang LM
    . 2013. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan. Pediatr Pulmonol48:904–911. doi:10.1002/ppul.22706.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Wu HM,
    2. Wong KS,
    3. Huang YC,
    4. Lai SH,
    5. Tsao KC,
    6. Lin YJ,
    7. Lin TY
    . 2013. Macrolide-resistant Mycoplasma pneumoniae in children in Taiwan. J Infect Chemother19:782–786. doi:10.1007/s10156-012-0523-3.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Gnarpe J,
    2. Lundback A,
    3. Gnarpe H,
    4. Sundelof B
    . 1997. Comparison of nasopharyngeal and throat swabs for the detection of Chlamydia pneumoniae and Mycoplasma pneumoniae by polymerase chain reaction. Scand J Infect Dis Suppl104:11–12.
    OpenUrlPubMed
  7. 7.↵
    1. Raty R,
    2. Ronkko E,
    3. Kleemola M
    . 2005. Sample type is crucial to the diagnosis of Mycoplasma pneumoniae pneumonia by PCR. J Med Microbiol54:287–291. doi:10.1099/jmm.0.45888-0.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Reznikov M,
    2. Blackmore TK,
    3. Finlay-Jones JJ,
    4. Gordon DL
    . 1995. Comparison of nasopharyngeal aspirates and throat swab specimens in a polymerase chain reaction-based test for Mycoplasma pneumoniae. Eur J Clin Microbiol Infect Dis14:58–61. doi:10.1007/BF02112622.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Waris ME,
    2. Toikka P,
    3. Saarinen T,
    4. Nikkari S,
    5. Meurman O,
    6. Vainionpaa R,
    7. Mertsola J,
    8. Ruuskanen O
    . 1998. Diagnosis of Mycoplasma pneumoniae pneumonia in children. J Clin Microbiol36:3155–3159.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Dorigo-Zetsma JW,
    2. Zaat SA,
    3. Wertheim-van Dillen PM,
    4. Spanjaard L,
    5. Rijntjes J,
    6. van Waveren G,
    7. Jensen JS,
    8. Angulo AF,
    9. Dankert J
    . 1999. Comparison of PCR, culture, and serological tests for diagnosis of Mycoplasma pneumoniae respiratory tract infection in children. J Clin Microbiol37:14–17.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Maltezou HC,
    2. La-Scola B,
    3. Astra H,
    4. Constantopoulou I,
    5. Vlahou V,
    6. Kafetzis DA,
    7. Constantopoulos AG,
    8. Raoult D
    . 2004. Mycoplasma pneumoniae and Legionella pneumophila in community-acquired lower respiratory tract infections among hospitalized children: diagnosis by real-time PCR. Scand J Infect Dis36:639–642.
    OpenUrlPubMed
  12. 12.↵
    1. Michelow IC,
    2. Olsen K,
    3. Lozano J,
    4. Duffy LB,
    5. McCracken GH,
    6. Hardy RD
    . 2004. Diagnostic utility and clinical significance of naso- and oropharyngeal samples used in a PCR assay to diagnose Mycoplasma pneumoniae infection in children with community-acquired pneumonia. J Clin Microbiol42:3339–3341. doi:10.1128/JCM.42.7.3339-3341.2004.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Skakni L,
    2. Sardet A,
    3. Just J,
    4. Landman-Parker J,
    5. Costil J,
    6. Moniot-Ville N,
    7. Bricout F,
    8. Garbarg-Chenon A
    . 1992. Detection of Mycoplasma pneumoniae in clinical samples from pediatric patients by polymerase chain reaction. J Clin Microbiol30:2638–2643.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Templeton KE,
    2. Scheltinga SA,
    3. Graffelman AW,
    4. Van Schie JM,
    5. Crielaard JW,
    6. Sillekens P,
    7. Van Den Broek PJ,
    8. Goossens H,
    9. Beersma MF,
    10. Claas EC
    . 2003. Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of Mycoplasma pneumoniae. J Clin Microbiol41:4366–4371. doi:10.1128/JCM.41.9.4366-4371.2003.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Spuesens EB,
    2. Fraaij PL,
    3. Visser EG,
    4. Hoogenboezem T,
    5. Hop WC,
    6. van Adrichem LN,
    7. Weber F,
    8. Moll HA,
    9. Broekman B,
    10. Berger MY,
    11. van Rijsoort-Vos T,
    12. van Belkum A,
    13. Schutten M,
    14. Pas SD,
    15. Osterhaus AD,
    16. Hartwig NG,
    17. Vink C,
    18. van Rossum AM
    . 2013. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med10:e1001444. doi:10.1371/journal.pmed.1001444.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Ponka A,
    2. Ponka T,
    3. Sarna S,
    4. Penttinen K
    . 1981. Questionable specificity of lipid antigen in the Mycoplasma pneumoniae complement fixation test in patients with extrapulmonary manifestations. J Infect3:332–338. doi:10.1016/S0163-4453(81)91901-0.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Kleemola M,
    2. Kayhty H
    . 1982. Increase in titers of antibodies to Mycoplasma pneumoniae in patients with purulent meningitis. J Infect Dis146:284–288. doi:10.1093/infdis/146.2.284.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Sillis M
    . 1990. The limitations of IgM assays in the serological diagnosis of Mycoplasma pneumoniae infections. J Med Microbiol33:253–258. doi:10.1099/00222615-33-4-253.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Thacker WL,
    2. Talkington DF
    . 2000. Analysis of complement fixation and commercial enzyme immunoassays for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol7:778–780.
    OpenUrlPubMed
  20. 20.↵
    1. Granstrom M,
    2. Holme T,
    3. Sjogren AM,
    4. Ortqvist A,
    5. Kalin M
    . 1994. The role of IgA determination by ELISA in the early serodiagnosis of Mycoplasma pneumoniae infection, in relation to IgG and mu-capture IgM methods. J Med Microbiol40:288–292. doi:10.1099/00222615-40-4-288.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Yamazaki T,
    2. Narita M,
    3. Sasaki N,
    4. Kenri T,
    5. Arakawa Y,
    6. Sasaki T
    . 2006. Comparison of PCR for sputum samples obtained by induced cough and serological tests for diagnosis of Mycoplasma pneumoniae infection in children. Clin Vaccine Immunol13:708–710. doi:10.1128/CVI.00413-05.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Beersma MF,
    2. Dirven K,
    3. van Dam AP,
    4. Templeton KE,
    5. Claas EC,
    6. Goossens H
    . 2005. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the “gold standard.” J Clin Microbiol43:2277–2285.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Lieberman D,
    2. Lieberman D,
    3. Ben-Yaakov M,
    4. Shmarkov O,
    5. Gelfer Y,
    6. Varshavsky R,
    7. Ohana B,
    8. Lazarovich Z,
    9. Boldur I
    . 2002. Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD. Diagn Microbiol Infect Dis44:1–6. doi:10.1016/S0732-8893(02)00421-2.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Lieberman D,
    2. Lieberman D,
    3. Korsonsky I,
    4. Ben-Yaakov M,
    5. Lazarovich Z,
    6. Friedman MG,
    7. Dvoskin B,
    8. Leinonen M,
    9. Ohana B,
    10. Boldur I
    . 2002. A comparative study of the etiology of adult upper and lower respiratory tract infections in the community. Diagn Microbiol Infect Dis42:21–28. doi:10.1016/S0732-8893(01)00324-8.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Watkins-Riedel T,
    2. Stanek G,
    3. Daxboeck F
    . 2001. Comparison of SeroMP IgA with four other commercial assays for serodiagnosis of Mycoplasma pneumoniae pneumonia. Diagn Microbiol Infect Dis40:21–25. doi:10.1016/S0732-8893(01)00250-4.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Jolliff CR,
    2. Cost KM,
    3. Stivrins PC,
    4. Grossman PP,
    5. Nolte CR,
    6. Franco SM,
    7. Fijan KJ,
    8. Fletcher LL,
    9. Shriner HC
    . 1982. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem28:126–128.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Kilian M,
    2. Mestecky J,
    3. Russell MW
    . 1988. Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol Rev52:296–303.
    OpenUrlFREE Full Text
  28. 28.↵
    1. Chang HY,
    2. Chang LY,
    3. Shao PL,
    4. Lee PI,
    5. Chen JM,
    6. Lee CY,
    7. Lu CY,
    8. Huang LM
    . 2014. Comparison of real-time polymerase chain reaction and serological tests for the confirmation of Mycoplasma pneumoniae infection in children with clinical diagnosis of atypical pneumonia. J Microbiol Immunol Infect47:137–144. doi:10.1016/j.jmii.2013.03.015.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Medjo B,
    2. Atanaskovic-Markovic M,
    3. Radic S,
    4. Nikolic D,
    5. Lukac M,
    6. Djukic S
    . 2014. Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children: clinical features and laboratory diagnosis. Ital J Pediatr40:104. doi:10.1186/s13052-014-0104-4.
    OpenUrlCrossRef
  30. 30.↵
    1. Ma YJ,
    2. Wang SM,
    3. Cho YH,
    4. Shen CF,
    5. Liu CC,
    6. Chi H,
    7. Huang YC,
    8. Huang LM,
    9. Huang YC,
    10. Lin HC,
    11. Ho YH,
    12. Mu JJ
    ,Taiwan Pediatric Infectious Disease Alliance. 2015. Clinical and epidemiological characteristics in children with community-acquired mycoplasma pneumonia in Taiwan: a nationwide surveillance. J Microbiol Immunol Infect48:632–638. doi:10.1016/j.jmii.2014.08.003.
    OpenUrlCrossRef
  31. 31.↵
    1. Busson L,
    2. Van den Wijngaert S,
    3. Dahma H,
    4. Decolvenaer M,
    5. Di Cesare L,
    6. Martin A,
    7. Vasseur L,
    8. Vandenberg O
    . 2013. Evaluation of 10 serological assays for diagnosing Mycoplasma pneumoniae infection. Diagn Microbiol Infect Dis76:133–137. doi:10.1016/j.diagmicrobio.2013.02.027.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Gavranich JB,
    2. Chang AB
    . 2005. Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev doi:10.1002/14651858.CD004875.pub2:CD004875.
    OpenUrlCrossRef
  33. 33.↵
    1. Klinger MH,
    2. Jelkmann W
    . 2002. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res22:913–922. doi:10.1089/10799900260286623.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Youn YS,
    2. Lee KY,
    3. Hwang JY,
    4. Rhim JW,
    5. Kang JH,
    6. Lee JS,
    7. Kim JC
    . 2010. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. BMC Pediatr10:48. doi:10.1186/1471-2431-10-48.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Lee SC,
    2. Youn YS,
    3. Rhim JW,
    4. Kang JH,
    5. Lee KY
    . 2016. Early serologic diagnosis of Mycoplasma pneumoniae pneumonia: an observational study on changes in titers of specific-IgM antibodies and cold agglutinins. Medicine (Baltimore, MD)95:e3605. doi:10.1097/MD.0000000000003605.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
Role of Serum Mycoplasma pneumoniae IgA, IgM, and IgG in the Diagnosis of Mycoplasma pneumoniae-Related Pneumonia in School-Age Children and Adolescents
Wei-Ju Lee, Eng-Yen Huang, Chih-Min Tsai, Kuang-Che Kuo, Yi-Chuan Huang, Kai-Sheng Hsieh, Chen-Kuang Niu, Hong-Ren Yu
Clinical and Vaccine Immunology Jan 2017, 24 (1) e00471-16; DOI: 10.1128/CVI.00471-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Role of Serum Mycoplasma pneumoniae IgA, IgM, and IgG in the Diagnosis of Mycoplasma pneumoniae-Related Pneumonia in School-Age Children and Adolescents
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Role of Serum Mycoplasma pneumoniae IgA, IgM, and IgG in the Diagnosis of Mycoplasma pneumoniae-Related Pneumonia in School-Age Children and Adolescents
Wei-Ju Lee, Eng-Yen Huang, Chih-Min Tsai, Kuang-Che Kuo, Yi-Chuan Huang, Kai-Sheng Hsieh, Chen-Kuang Niu, Hong-Ren Yu
Clinical and Vaccine Immunology Jan 2017, 24 (1) e00471-16; DOI: 10.1128/CVI.00471-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antibodies, Bacterial
Immunoglobulin A
Immunoglobulin G
immunoglobulin M
Mycoplasma pneumoniae
Pneumonia, Mycoplasma
Serologic Tests
Mycoplasma pneumoniae IgA
Mycoplasma pneumoniae IgM
paired sera
pneumonia
school-age children
mycoplasma pneumonia IgA
mycoplasma pneumonia IgM

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X